Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Discovery

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-16-0860PMID 28003236PMCID PMC5300099
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate‐risk and high‐risk head and neck squamous cell carcinoma

  2021cited by this paper
• Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

  2020cited by this paper
• A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer

  2020cited by this paper
• Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

  2020cited by this paper
• BRCAness revisited

  2016cited by this paper
• Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

  2016cited by this paper
• Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

  2016cited by this paper
• Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations

  2016cited by this paper
• A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.

  2016cited by this paper
• Linking DNA Damage and Hormone Signaling Pathways in Cancer.

  2016cited by this paper
• G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status

  2016cited by this paper
• Shelterin.

  2016cited by this paper
• Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

  2016cited by this paper
• Drugging DNA repair

  2016cited by this paper
• Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

  2016cited by this paper
• Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).

  2016cited by this paper
• Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

  2016cited by this paper
• PARP inhibitors: the race is on

  2016cited by this paper
• Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792)

  2016cited by this paper
• Repair Pathway Choices and Consequences at the Double-Strand Break.

  2016influential reference
• Phase ib trial of dose-escalating AZD1775 in combination with concurrent radiation and cisplatin for intermediate and high risk head and neck squamous cell carcinoma.

  2016cited by this paper
• Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.

  2016cited by this paper
• Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.

  2016influential reference
• A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts.

  2016cited by this paper
• Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers.

  2016cited by this paper
• A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.

  2016cited by this paper
• New directions in poly(ADP‐ribose) polymerase biology

  2016cited by this paper
• Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

  2016cited by this paper
• Replication stress and cancer

  2015cited by this paper
• The DNA-dependent protein kinase: A multifunctional protein kinase with roles in DNA double strand break repair and mitosis.

  2015cited by this paper
• Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

  2015cited by this paper
• Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

  2015cited by this paper
• WEE1 Kinase As a Target for Cancer Therapy.

  2015cited by this paper
• Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

  2015cited by this paper
• ATM and ATR Signaling Regulate the Recruitment of Human Telomerase to Telomeres.

  2015cited by this paper
• An update on PARP inhibitors—moving to the adjuvant setting

  2015cited by this paper
• Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

  2015cited by this paper
• CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

  2015cited by this paper
• PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair

  2015cited by this paper
• Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors

  2015cited by this paper
• Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

  2015cited by this paper
• Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination

  2015cited by this paper
• Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.

  2015cited by this paper
• Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

  2015cited by this paper
• Olaparib combined with abiraterone in patients with metastatic prostate cancer: Safety run-in from a phase II study.

  2015cited by this paper
• Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair

  2015cited by this paper
• Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.

  2015influential reference
• Ubiquitylation, neddylation and the DNA damage response

  2015cited by this paper
• Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

  2015cited by this paper
• Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

  2015cited by this paper
• Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy.

  2015cited by this paper
• An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.

  2015cited by this paper
• A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

  2015cited by this paper
• Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy.

  2015cited by this paper
• Neddylation Promotes Ubiquitylation and Release of Ku from DNA-Damage Sites

  2015cited by this paper
• How cancer cells hijack DNA double-strand break repair pathways to gain genomic instability.

  2015cited by this paper
• Abstract 2745: Pharmacological characterisation of cell active inhibitors of Poly(ADP-ribose) glycohydrolase (PARG)

  2014cited by this paper
• Beyond DNA repair: DNA-PK function in cancer.

  2014cited by this paper
• Molecular Pathways Molecular Pathways : How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors ?

  2014cited by this paper
• Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy

  2014cited by this paper
• MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool

  2014cited by this paper
• Small-Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases

  2014influential reference
• Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

  2014cited by this paper
• Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

  2014cited by this paper
• Mechanisms underlying mutational signatures in human cancers

  2014cited by this paper
• Double strand break (DSB) repair in heterochromatin and heterochromatin proteins in DSB repair.

  2014cited by this paper
• Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes

  2014cited by this paper
• Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink

  2014cited by this paper
• Targeting ATR in DNA damage response and cancer therapeutics.

  2014cited by this paper
• Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

  2014cited by this paper
• Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

  2014cited by this paper
• New and emerging HDAC inhibitors for cancer treatment.

  2014cited by this paper
• A quantitative 14-3-3 interaction screen connects the nuclear exosome targeting complex to the DNA damage response

  2014cited by this paper
• DNA damage and innate immunity: links and trade-offs.

  2014cited by this paper
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• Alternative end-joining pathway(s): bricolage at DNA breaks.

  2014cited by this paper
• Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways

  2014cited by this paper
• One ring to bring them all--the role of Ku in mammalian non-homologous end joining.

  2014cited by this paper
• DNA single-strand break repair.

  2014cited by this paper
• Structure-based design , discovery and development of checkpoint kinase inhibitors as potential anti-cancer therapies

  2014cited by this paper
• Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL).

  2014cited by this paper
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

  2014cited by this paper
• Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).

  2014cited by this paper
• Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).

  2014cited by this paper
• VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.

  2014cited by this paper
• Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.

  2014cited by this paper
• Wee1 kinase as a target for cancer therapy

  2013cited by this paper
• BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations

  2013cited by this paper
• Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies

  2013cited by this paper
• DNA double strand break repair via non-homologous end-joining.

  2013influential reference
• A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors

  2013cited by this paper
• DNA damage sensing by the ATM and ATR kinases.

  2013cited by this paper

• Targeting Galectin-9 to overcome immunosuppression and potentiate ATR inhibitor therapy.

  2026cites this paper
• Cancer-associated fibroblasts: enablers of tumor drug resistance

  2026cites this paper
• Homoisoflavanone Delays Colorectal Cancer Progression via DNA Damage-Induced Mitochondrial Apoptosis and Parthanatos-Like Cell Death.

  2026cites this paper
• Immune Evasion in Pancreatic Ductal Adenocarcinoma: Mechanistic Insights and Emerging Strategies to Reinvigorate Anti-Cancer Immunity

  2026cites this paper
• Design and synthesis of c-Met/PARP dual-target inhibitors for the treatment of BRCA wild-type TNBC.

  2026cites this paper
• Oral Cancer Stem Cells: A Comprehensive Review of Key Drivers of Treatment Resistance and Tumor Recurrence.

  2025cites this paper
• Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs

  2025cites this paper
• Targeting DNA damage response to enhance cancer immunotherapy efficacy: molecular mechanisms and clinical advances

  2025cites this paper
• Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine.

  2025cites this paper
• ATM inhibitors in cancer radiotherapy: Mechanisms, clinical development, and future directions.

  2025cites this paper
• Tandem Synthesis and Computational Insights into Triazole and Pyrazole-Based Pyridine Derivatives Targeting EGFR-TK in Cancer Therapy

  2025cites this paper
• Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer

  2025cites this paper
• Hyperthermia-induced BRCA2 reduction potentiates PARPi sensitivity in BRCA2-proficient ovarian carcinoma

  2025cites this paper
• The MCM6-c-Myc positive feedback loop mediates bladder cancer progression and cisplatin resistance.

  2025cites this paper
• A prognostic model of lung adenocarcinoma constructed based on circadian rhythm genes and its potential clinical significance

  2025cites this paper
• TopBP1 biomolecular condensates as a new therapeutic target in advanced-stage colorectal cancer

  2025cites this paper
• Potential protective regulatory effects on radiation−induced esophageal injury in TUT4−/− mice

  2025cites this paper
• DNA repair pathways in ovarian cancer: Implications for therapy and resistance.

  2025cites this paper
• Deubiquitinases in DNA damage repair: Implication and mechanism in cancer.

  2025cites this paper
• Checkpoint-Dependent Sensitivities to Nucleoside Analogues Uncover Specific Patterns of Genomic Instability

  2025cites this paper
• Tetrahedral Framework Nucleic Acids Inhibit Oxidative Stress and Cardiomyocyte Apoptosis in Doxorubicin-Induced Cardiotoxicity

  2025cites this paper
• YWHAG promotes the progression of lung adenocarcinoma through the JAK2/STAT3 pathway

  2025cites this paper
• Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study

  2025cites this paper
• Metabolites beyond metabolism: Exploring their atypical roles in protein modification and signaling transduction

  2025cites this paper
• TopBP1 biomolecular condensates: a new therapeutic target in advanced-stage colorectal cancer

  2025cites this paper
• Designing an anticancer Pd(II) complex as poly(ADP-ribose) polymerase 1 inhibitor.

  2025cites this paper
• Multi-omics analysis identifies LANCL2 as a potential biomarker for the diagnosis and prognosis of gastric cancer

  2025cites this paper
• Susceptibility of Brca1 (L63X/+) rat to ovarian reserve dissipation by chemotherapeutic agents to breast cancer

  2025cites this paper
• Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors

  2025cites this paper
• Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions

  2025cites this paper
• Clinical significance and molecular mechanism of CDX2-CBX3 regulatory axis in lung adenocarcinoma progression

  2025cites this paper
• Prp19/CDC5L promotes gastric cancer via activation of the MAPK pathway-mediated homologous recombination

  2025cites this paper
• Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer

  2025cites this paper
• ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results

  2025cites this paper
• Multidimensional pan-cancer analysis reveals the impact of PPIA on tumor epigenetic modifications and immune regulation

  2025cites this paper
• Coordinated protein modules define DNA damage responses to carboplatin at single-cell resolution in human ovarian carcinoma models

  2025cites this paper
• Design, development, and therapeutic applications of PARP-1 selective inhibitors.

  2025cites this paper
• Chinese agarwood petroleum ether extract suppressed gastric cancer progression via up-regulation of DNA damage-induced G0/G1 phase arrest and HO-1-mediated ferroptosis.

  2025cites this paper
• Germline Mutations in DNA Repair Genes in Patients with Pancreatic Neuroendocrine Neoplasms: Diagnostic and Therapeutic Implications

  2025cites this paper
• Germline Mutations as Cancer Drug Targets.

  2025cites this paper
• Shining light on drug discovery: optogenetic screening for TopBP1 biomolecular condensate inhibitors

  2025cites this paper
• Targeting the CXCR4/CXCL12 Axis to Overcome Drug Resistance in Triple-Negative Breast Cancer

  2025cites this paper
• RNF11 confers chemotherapy sensitivity to tumor cells by regulating the ubiquitination of KU80 and the cell cycle.

  2025cites this paper
• Energy Deficiency‐Induced ATG4B Nuclear Translocation Inhibits PRMT1‐Mediated DNA Repair and Promotes Leukemia Progression

  2025cites this paper
• Association Between Seven Selected Genetic Polymorphisms in DNA Repair-Related Genes and Breast Cancer Risk: Evidence from a Comprehensive Meta-analysis Including 96 Studies.

  2025cites this paper
• Discovery of 1H-Pyrrolo[2,3-b]pyridine Derivatives as Highly Selective, and Orally Available ATM Inhibitors with Potent In Vivo Antitumor Activity.

  2025cites this paper
• The Tight Relationship Between the Tumoral Microenvironment and Radium-223

  2025cites this paper
• FET proteins and PARylation-dependent condensates promote replication fork reversal and genome stability

  2025cites this paper
• Mitophagy-related gene TRIP13 predicts prognosis and immune response and promotes proliferation and migration in vitro and in vivo of clear cell renal cell carcinoma

  2025cites this paper
• Esophageal Cancer Cells Exhibit Heterogeneity in DNA Double-Strand Break Repair and G2/M Checkpoint Arrest Associated With Cell Viability After Ionizing Radiation.

  2025cites this paper
• Cost-Effectiveness of PARP Inhibitors for Patients with BRCA1/2-Positive Metastatic Castration-Resistant Prostate Cancer—The Canadian Perspective

  2024cites this paper
• PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for

  2024cites this paper
• Insights into the behaviour of phosphorylated DNA breaks from molecular dynamic simulations

  2024cites this paper
• Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms

  2024cites this paper
• Equol promotes the in vitro maturation of porcine oocytes by activating the NRF2/KEAP1 signaling pathway.

  2024cites this paper
• Real-world TRAE association between niraparib and platinum-based chemotherapy

  2024cites this paper
• Comment on “gemcitabine, PI3kinase-Akt pathway inhibition and radiation in human glioma cell lines” by M.S. Elnaggar et al.1

  2024cites this paper
• Canonical and Non-Canonical Roles of Human DNA Polymerase η

  2024cites this paper
• Potential promising of synthetic lethality in cancer research and treatment

  2024influential citation
• Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models

  2024cites this paper
• Enhancing PARP inhibitor efficacy using reduction-responsive nanoparticles encapsulating NADP.

  2024cites this paper
• Repurposing the Antihypertensive Agent Hydralazine As an Inhibitor of the Base Excision Repair Enzyme APE1.

  2024cites this paper
• In silico study of novel coumarin derivatives as potential agents in the pancreatic cancer treatment.

  2024cites this paper
• Multilevel Mechanisms of Cancer Drug Resistance

  2024cites this paper
• ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation

  2024cites this paper
• UCHL3 induces radiation resistance and acquisition of mesenchymal phenotypes by deubiquitinating POLD4 in glioma stem cells

  2024cites this paper
• Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis

  2024cites this paper
• Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship.

  2024cites this paper
• Clinical and molecular features of platinum resistance in ovarian cancer.

  2024cites this paper
• Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options

  2024cites this paper
• Inactivation of VRK1 Sensitizes Ovarian Cancer to PARP Inhibition through regulating DNA-PK stability.

  2024cites this paper
• Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib

  2024influential citation
• PARP inhibitor boost the efficacy of photothermal therapy to TNBC through enhanced DNA damage and inhibited homologous recombination repair

  2024cites this paper
• Discovery of selective and potent ATR degrader for exploration its kinase-independent functions in acute myeloid leukemia cells.

  2024cites this paper
• Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment.

  2024cites this paper
• POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

  2024cites this paper
• Genome-aware annotation of CRISPR guides validates targets in variant cell lines and enhances discovery in screens

  2024cites this paper
• GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas

  2024cites this paper
• A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer

  2024cites this paper
• Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers

  2024cites this paper
• Radiosensitizing Effect of PARP Inhibition on Chondrosarcoma and Chondrocyte Cells Is Dependent on Radiation LET

  2024cites this paper
• The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

  2024cites this paper
• Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer

  2024cites this paper
• Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours

  2024cites this paper
• αKG-mediated carnitine synthesis promotes homologous recombination via histone acetylation

  2024cites this paper
• For better or worse: crosstalk of parvovirus and host DNA damage response

  2024cites this paper
• FSHing for DNA Damage: Key Features of MutY Detection of 8-Oxoguanine:Adenine Mismatches

  2024cites this paper
• Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells

  2024cites this paper
• Identification of MAD2L1 and BUB1B as Potential Biomarkers Associated with Progression and Prognosis of Ovarian Cancer

  2024cites this paper
• Structure-specific nucleases in genome dynamics and strategies for targeting cancers

  2024cites this paper
• BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy

  2024cites this paper
• Molecular Pathology of Prostate Cancer.

  2024cites this paper
• Chromatin regulators in DNA replication and genome stability maintenance during S-phase.

  2023cites this paper
• Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel

  2023cites this paper
• Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer

  2023cites this paper
• Triumphs and challenges in exploiting poly(ADP‐ribose) polymerase inhibition to combat triple‐negative breast cancer

  2023influential citation
• Recent advances in the role of endogenous hydrogen sulphide in cancer cells

  2023cites this paper
• Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma through m6A-mediated epitranscriptomic regulation

  2023cites this paper
• VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer

  2023cites this paper
• Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials

  2023cites this paper